Trial intelligence / Profile preview

Dasatinib 70 mg vs 100 mg First-Line in Chronic Phase CML (Yinishu)

ChiCTR2000041242Phase 4Recruiting

Sponsor
Union Hospital
Start
Jul 2019
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4, randomised trial of dasatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Union Hospital. Primary endpoints: CCyR rate at 12 months, MMR rate at 12 months and 2 more. Started Jul 2019; status: recruiting.

02

Drugs

dasatinib
03

Conditions

chronic myelogenous leukemia (CML)

Beyond the preview

Go deeper on ChiCTR2000041242.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ChiCTR2000041242.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call